ATE311890T1 - Dispergierbare zusammensetzungen von macroliden und verfahren zu deren herstellung - Google Patents

Dispergierbare zusammensetzungen von macroliden und verfahren zu deren herstellung

Info

Publication number: ATE311890T1
Authority: AT; Austria
Prior art keywords: agent; macrolids; production; sweetening agent; dispersible compositions
Prior art date: 1999-03-30

Application number

AT00915252T

Other languages

English (en)

Inventor

Noel Zakarian

Rene Gimet

Claude Laruelle

Dominique Toselli

Original Assignee

Cll Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-30

Filing date

2000-03-30

Publication date

2005-12-15

2000-03-30 Application filed by Cll Pharma filed Critical Cll Pharma

2005-12-15 Application granted granted Critical

2005-12-15 Publication of ATE311890T1 publication Critical patent/ATE311890T1/de

Links

239000000203 mixture Substances 0.000 title abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 3
235000003599 food sweetener Nutrition 0.000 abstract 2
239000003765 sweetening agent Substances 0.000 abstract 2
RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 abstract 1
ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 abstract 1
YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 abstract 1
YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 abstract 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 abstract 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
108010011485 Aspartame Proteins 0.000 abstract 1
IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 abstract 1
RLNUPSVMIYRZSM-UHFFFAOYSA-N Pristinamycin Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)CCN(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O RLNUPSVMIYRZSM-UHFFFAOYSA-N 0.000 abstract 1
108010079780 Pristinamycin Proteins 0.000 abstract 1
239000004187 Spiramycin Substances 0.000 abstract 1
HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 abstract 1
239000000605 aspartame Substances 0.000 abstract 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical group OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 abstract 1
235000010357 aspartame Nutrition 0.000 abstract 1
229960003438 aspartame Drugs 0.000 abstract 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 abstract 1
229960004099 azithromycin Drugs 0.000 abstract 1
230000003115 biocidal effect Effects 0.000 abstract 1
229960002626 clarithromycin Drugs 0.000 abstract 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
239000007919 dispersible tablet Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000000796 flavoring agent Substances 0.000 abstract 1
235000019634 flavors Nutrition 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
229960000282 metronidazole Drugs 0.000 abstract 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 abstract 1
229960002313 ornidazole Drugs 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
229960003961 pristinamycin Drugs 0.000 abstract 1
DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 abstract 1
JOOMGSFOCRDAHL-XKCHLWDXSA-N pristinamycin-IIB Natural products CC(C)[C@@H]1OC(=O)[C@H]2CCCN2C(=O)c3coc(CC(=O)C[C@@H](O)C=C(C)C=CCNC(=O)C=C[C@H]1C)n3 JOOMGSFOCRDAHL-XKCHLWDXSA-N 0.000 abstract 1
229960005224 roxithromycin Drugs 0.000 abstract 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 abstract 1
229960001294 spiramycin Drugs 0.000 abstract 1
229930191512 spiramycin Natural products 0.000 abstract 1
235000019372 spiramycin Nutrition 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 abstract 1
229960005053 tinidazole Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nutrition Science (AREA)
Zoology (AREA)
Physiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

AT00915252T 1999-03-30 2000-03-30 Dispergierbare zusammensetzungen von macroliden und verfahren zu deren herstellung ATE311890T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9903978A FR2793690B1 (fr)	1999-03-30	1999-03-30	Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
PCT/FR2000/000800 WO2000057886A1 (fr)	1999-03-30	2000-03-30	Composes dispersibles de macrolides et leur procede de preparation

Publications (1)

Publication Number	Publication Date
ATE311890T1 true ATE311890T1 (de)	2005-12-15

Family

ID=9543821

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00915252T ATE311890T1 (de)	1999-03-30	2000-03-30	Dispergierbare zusammensetzungen von macroliden und verfahren zu deren herstellung

Country Status (13)

Country	Link
US (1)	US6605301B2 (de)
EP (2)	EP1165094B1 (de)
AT (1)	ATE311890T1 (de)
AU (1)	AU3662700A (de)
BR (1)	BR0009447A (de)
CA (1)	CA2368880A1 (de)
DE (1)	DE60024601T2 (de)
DZ (1)	DZ3149A1 (de)
ES (1)	ES2254158T3 (de)
FR (1)	FR2793690B1 (de)
MA (1)	MA25526A1 (de)
MX (1)	MXPA01009845A (de)
WO (1)	WO2000057886A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE432691T1 (de) *	2000-03-28	2009-06-15	Sandoz Ag	Geschmackmaskierte granulierte teilchen
GB0123400D0 (en)	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
NZ532707A (en) *	2001-12-21	2006-07-28	Pfizer Prod Inc	Directly compressible formulations of azithromycin
MXPA04007427A (es)	2002-02-01	2004-10-11	Pfizer Prod Inc	Formulaciones de azitromicina granuladas por via seca.
GB0223978D0 (en) *	2002-10-15	2002-11-20	Novartis Ag	Organic compound
US20050196455A1 (en) *	2003-10-27	2005-09-08	Jianbing Chen	Suspension delivery system for the sustained and controlled local release of pharmaceuticals
US6984403B2 (en)	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
JP2007513147A (ja)	2003-12-04	2007-05-24	ファイザー・プロダクツ・インク	押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2007008537A2 (en) *	2005-07-07	2007-01-18	Elan Pharma International, Limited	Nanoparticulate clarithromycin formulations
EP1906937B1 (de) *	2005-07-22	2016-10-19	Rubicon Research Pvt Ltd.	Neuartige dispergierbare tabletten zusammensetzung
CN100348190C (zh) *	2005-09-14	2007-11-14	北京正大绿洲医药科技有限公司	奥硝唑滴丸及其制备方法
EP2201939A1 (de)	2008-12-25	2010-06-30	Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S.	Verfahrung zur Herstellung von beschichtetem Spiramycin und neue Formulierungen damit
CN104825408A (zh) *	2012-12-31	2015-08-12	四川科伦药业股份有限公司	一种阿奇霉素分散片及其制备方法和用途
CN104739792B (zh) *	2015-04-17	2017-11-10	四川科伦药业股份有限公司	一种罗红霉素分散片制备方法
GR1008992B (el)	2015-12-17	2017-03-23	Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων	Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης
CN108619105A (zh) *	2018-07-26	2018-10-09	江苏黄河药业股份有限公司	一种阿奇霉素分散片
CN108853039B (zh) *	2018-08-07	2021-03-09	河北君临药业有限公司	一种克拉霉素分散片及其生产工艺
CN109528672B (zh) *	2019-01-30	2021-03-16	河北君临药业有限公司	一种乙酰螺旋霉素片及其制备方法
CN110548010A (zh) *	2019-04-02	2019-12-10	海南海神同洲制药有限公司	一种罗红霉素分散片制备方法
CN111388444B (zh) *	2020-03-18	2022-05-20	北京鑫开元医药科技有限公司	一种罗红霉素颗粒及其制备方法
CN114948887A (zh) *	2022-06-17	2022-08-30	中山可可康制药有限公司	一种克拉霉素分散片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5106967A (en) *	1988-05-05	1992-04-21	The Procter & Gamble Company	Functional sugar substitutes with reduced calories
IT1246383B (it) *	1990-04-17	1994-11-18	Eurand Int	Metodo per il mascheramento del sapore di farmaci
US5192752A (en) *	1991-01-14	1993-03-09	The Procter & Gamble Company	Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
FR2696346B1 (fr) *	1992-10-05	1994-11-25	Rhone Poulenc Rorer Sa	Nouvelles formulations pharmaceutiques de spiramycine.
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin

1999
- 1999-03-30 FR FR9903978A patent/FR2793690B1/fr not_active Expired - Fee Related
2000
- 2000-03-30 DE DE60024601T patent/DE60024601T2/de not_active Expired - Lifetime
- 2000-03-30 WO PCT/FR2000/000800 patent/WO2000057886A1/fr not_active Ceased
- 2000-03-30 MX MXPA01009845A patent/MXPA01009845A/es active IP Right Grant
- 2000-03-30 BR BR0009447-1A patent/BR0009447A/pt not_active Application Discontinuation
- 2000-03-30 EP EP00915252A patent/EP1165094B1/de not_active Expired - Lifetime
- 2000-03-30 CA CA002368880A patent/CA2368880A1/fr not_active Abandoned
- 2000-03-30 ES ES00915252T patent/ES2254158T3/es not_active Expired - Lifetime
- 2000-03-30 DZ DZ003149A patent/DZ3149A1/xx active
- 2000-03-30 AU AU36627/00A patent/AU3662700A/en not_active Abandoned
- 2000-03-30 EP EP04025511A patent/EP1506780A3/de not_active Withdrawn
- 2000-03-30 AT AT00915252T patent/ATE311890T1/de not_active IP Right Cessation
2001
- 2001-09-28 US US09/966,669 patent/US6605301B2/en not_active Expired - Fee Related
- 2001-10-23 MA MA26380A patent/MA25526A1/fr unknown

Also Published As

Publication number	Publication date
US6605301B2 (en)	2003-08-12
FR2793690A1 (fr)	2000-11-24
ES2254158T3 (es)	2006-06-16
CA2368880A1 (fr)	2000-10-05
FR2793690B1 (fr)	2003-01-03
MA25526A1 (fr)	2002-10-01
AU3662700A (en)	2000-10-16
WO2000057886A1 (fr)	2000-10-05
EP1506780A3 (de)	2005-03-02
US20020061333A1 (en)	2002-05-23
MXPA01009845A (es)	2003-02-12
DZ3149A1 (fr)	2001-08-16
EP1506780A2 (de)	2005-02-16
EP1165094A1 (de)	2002-01-02
BR0009447A (pt)	2002-01-08
DE60024601T2 (de)	2006-09-14
EP1165094B1 (de)	2005-12-07
DE60024601D1 (de)	2006-01-12

Legal Events

Date

Code

Title

Description

2006-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1165094

Country of ref document: EP

2009-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60024601D1 (de)	2006-01-12	Dispergierbare zusammensetzungen von macroliden und verfahren zu deren herstellung
BG104841A (en)	2001-07-31	Fizzy formulations
CA2277824A1 (en)	1998-07-16	Dosage composition for nasal delivery and method of use of the same
IL188052A0 (en)	2008-03-20	A defecation promoting agent having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same
DK0850046T3 (da)	2003-03-03	Mikroemulsioner til anvendelse som vhikel til indgift af active forbindelser
KR950703327A (ko)	1995-09-20	씹을 수 있는 라니티딘 정제(Ranitidine Chewable Tablets)
CA2424664A1 (en)	2002-04-25	Novel non-imidazole compounds
EA200001010A1 (ru)	2001-02-26	Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
SK1452000A3 (en)	2001-05-10	Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
FR2786187B1 (fr)	2001-11-09	Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations
CA2314942A1 (en)	1999-06-10	Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
CA2094806A1 (en)	1992-05-08	Aminosulfonyl urea acat inhibitors
MA26644A1 (fr)	2004-12-20	Derives de 1,7, diaza-spiro (3,5) nonane, procede de preparation et medicament les contenant
IT1292130B1 (it)	1999-01-25	Processo per la preparazione dell'acido 1,4,7,10-tetraazaciclododecan -1,4,7-triacetico e suoi derivati
CA2329188A1 (en)	1999-11-04	Improved extrusion process
TR200002766T2 (tr)	2001-01-22	3',3'-N-Bis-ikameli makrolit LHRH Antagonistleri
TR200002767T2 (tr)	2001-05-21	Makrolit LHRH Antagonistleri
HUT73679A (en)	1996-09-30	N-{[1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl]-n-methylamino}-2-benzothiazolol derivatives class iii. antiarhythmic agents containing the same and process for their preparation
WO2000058328A3 (de)	2001-04-26	Avermectinderivate
DE59903063D1 (de)	2002-11-14	Semi-hydrochlorid von 8-cyan-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluor-1, 4-dihydro-4- oxo-3- chinolincarbonsäure
WO2000076457A3 (en)	2001-05-17	Il-8 receptor antagonists
AU2002215169A1 (en)	2002-05-27	Sanitizing composition containing chlorinated isocyanurate for in-ovo injection equipment
IE840977L (en)	1984-10-22	Pharmaceutical preparations
DE69729618D1 (de)	2004-07-29	Abführmittel und verfahren zu deren herstellung
BG103923A (en)	2000-06-30	Sulphate salt of hiv protease inhibitor with improved peroral absorption and biopresence